Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-MSCs, Calcipotriol, and PSORI-CM01 in Moderate to Severe Psoriasis
NCT04275024Completed
- Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Start
- Apr 2020
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Open-label trial of adipose-derived mesenchymal stem cells (Guangdong Provincial Hospital of Traditional Chinese Medicine) in Psoriasis vulgaris (PV), sponsored by Guangdong Provincial Hospital of Traditional Chinese Medicine. Primary endpoint: Psoriasis Area and Severity Index improvement rate at 12 weeks. Started Apr 2020; status: completed.
02
Drugs
adipose-derived mesenchymal stem cells (Guangdong Provincial Hospital of Traditional Chinese Medicine)
03
Conditions
Psoriasis vulgaris (PV)
Beyond the preview
Go deeper on NCT04275024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275024.